Information Hub

Clinical News

2020-06-22

The role of POLE mutation in immunotherapy

POLE encodes a protein for DNA replication. This retrospective study revealed that pathogenic POLE mutations are correlated with TMB-H and associated with a better outcome of immunotherapy.

Source:

Garmezy B. et al. 2020 ASCO

2020-06-22

Tipifarnib shows preliminary activities in HRAS-mutant head and neck cancer and urothelial cancer

In two phase II studies published at the 2020 ASCO Virtual Scientific Program, tipifarnib demonstrated potential anti-tumor effect in head and neck cancer or urothelial cancer patients. All the recruited patients had an HRAS mutation.

Source:

J Clin Oncol 38: 2020

2020-06-22

Trastuzumab deruxtecan demonstrates clinical activity in HER2-mutated NSCLC

According to data reported during the 2020 ASCO Virtual Scientific Meeting, trastuzumab deruxtecan showed promising activity with a high response rate and durable responses among NSCLC patients with HER2 mutation.

Source:

J Clin Oncol. 2020

2020-05-22

The current molecular biomarkers for treatment selection in NSCLC clinical practice

Molecular biomarkers play an important role in NSCLC disease management. There are 11 biomarkers listed in version 4.2020 of the NCCN guideline for NSCLC, including 8 FDA-approved biomarkers and 3 emerging biomarkers for novel therapies. These biomarkers

Source:

NCCN Guidelines

2020-05-22

Onvansertib regimen demonstrates anti-tumor activity in patients with metastatic KRAS-mutant CRC

There is an unmet need for treating the CRC patient who has a KRAS mutation. In a phase 1b/2 study, the combination of onvansertib, FOLFIRI, and bevacizumab as second-line treatment demonstrated significant clinical benefit in KRAS-mutant CRC.

Source:

Journal of Clinical Oncology 2020

2020-05-22

RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib demonstrates clinical activity among KRAS-mutant cancer patients

Currently, there is no approved KRAS targeted therapy, and it remains challenging to treat patients who harbor KRAS mutations. According to preliminary results form an ongoing phase 1 trial, defactinib plus RAF/MEK inhibitor is active in KRAS-mutant cance

Source:

2020 AACR

2020-05-08

Promising CSF genetic profiling for treatment assessment in brain metastases NSCLC patient

For the patients with EGFR T790M, who acquired resistance to first- and second-generation EGFR tyrosine inhibitors, osimertinib demonstrated promising efficacy.

Source:

Br J Cancer

2020-04-22

PTEN and ESR1 genetic alterations may be the resistance mechanisms in breast cancer patients received alpelisib plus aromatase inhibitors

A study used ctDNA for evaluation of the resistance mechanisms in HR+/Her2- metastatic breast cancer who were treated with alpelisib plus aromatase inhibitors. The results showed PTEN and ESR1 genetic alterations were associated with resistance.

Source:

Nat Cancer

2020-04-22

Fam-trastuzumab deruxtecan showed promising anti-tumor activity in multiple advanced solid tumors with HER2-overexpression and/or HER2 Mutation

In addition to breast cancer and gastric cancer, trastuzumab deruxtecan demonstrated promising activity in patients with HER2-expressing and/or HER2-mutant solid tumors in a phase I study.

Source:

Cancer Discov

2020-04-22

Trastuzumab plus chemotherapy demonstrated significant survival benefit in HER2-positive uterine serous carcinoma patients

In a phase 2 clinical trial, addition of trastuzumab to platinum-based chemotherapy showed an overall survival benefit in HER2-positive uterine serous carcinoma patients.

Source:

SGO 2020 Annual Meeting

青娱极品盛宴国产分类-亚洲 欧美 日韩 国产 制服-国产爆乳合集在线视频,五月色婷婷,久久热在线视频,免费网站看v片在线薰衣草